Correlation Between Neuropace and Tandem Diabetes

Can any of the company-specific risk be diversified away by investing in both Neuropace and Tandem Diabetes at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Tandem Diabetes into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and Tandem Diabetes Care, you can compare the effects of market volatilities on Neuropace and Tandem Diabetes and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Tandem Diabetes. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Tandem Diabetes.

Diversification Opportunities for Neuropace and Tandem Diabetes

0.09

Correlation Coefficient

Neuropace  Tandem Diabetes

Significant diversification

The 3 months correlation between Neuropace and Tandem is 0.09. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Tandem Diabetes Care in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tandem Diabetes Care and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Tandem Diabetes. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tandem Diabetes Care has no effect on the direction of Neuropace i.e., Neuropace and Tandem Diabetes go up and down completely randomly.

Pair Corralation between Neuropace and Tandem Diabetes

Given the investment horizon of 90 days Neuropace is expected to generate 0.7 times more return on investment than Tandem Diabetes. However, Neuropace is 1.44 times less risky than Tandem Diabetes. It trades about 0.04 of its potential returns per unit of risk. Tandem Diabetes Care is currently generating about -0.12 per unit of risk. If you would invest  1,119  in Neuropace on December 4, 2024 and sell it today you would earn a total of  65.00  from holding Neuropace or generate 5.81% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neuropace  vs.  Tandem Diabetes Care

Neuropace

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, Neuropace may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Tandem Diabetes Care

Risk-Adjusted Performance

Very Weak

Over the last 90 days Tandem Diabetes Care has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Neuropace and Tandem Diabetes

The main advantage of trading using opposite Neuropace and Tandem Diabetes positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Tandem Diabetes can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tandem Diabetes will offset losses from the drop in Tandem Diabetes' long position.

The idea behind Neuropace and Tandem Diabetes Care pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.